GB9217124D0 - Medical treatment - Google Patents

Medical treatment

Info

Publication number
GB9217124D0
GB9217124D0 GB929217124A GB9217124A GB9217124D0 GB 9217124 D0 GB9217124 D0 GB 9217124D0 GB 929217124 A GB929217124 A GB 929217124A GB 9217124 A GB9217124 A GB 9217124A GB 9217124 D0 GB9217124 D0 GB 9217124D0
Authority
GB
United Kingdom
Prior art keywords
medical treatment
medical
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB929217124A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antisoma Ltd
Original Assignee
Antisoma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antisoma Ltd filed Critical Antisoma Ltd
Priority to GB929217124A priority Critical patent/GB9217124D0/en
Publication of GB9217124D0 publication Critical patent/GB9217124D0/en
Priority to PCT/GB1993/001716 priority patent/WO1994004191A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GB929217124A 1992-08-13 1992-08-13 Medical treatment Pending GB9217124D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB929217124A GB9217124D0 (en) 1992-08-13 1992-08-13 Medical treatment
PCT/GB1993/001716 WO1994004191A1 (en) 1992-08-13 1993-08-13 Medical treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929217124A GB9217124D0 (en) 1992-08-13 1992-08-13 Medical treatment

Publications (1)

Publication Number Publication Date
GB9217124D0 true GB9217124D0 (en) 1992-09-23

Family

ID=10720235

Family Applications (1)

Application Number Title Priority Date Filing Date
GB929217124A Pending GB9217124D0 (en) 1992-08-13 1992-08-13 Medical treatment

Country Status (2)

Country Link
GB (1) GB9217124D0 (en)
WO (1) WO1994004191A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19826307A1 (en) * 1998-03-08 1999-12-16 Wolfgang Bergter CD4 radio immunological pharmaceuticals
DE19809785C2 (en) * 1998-03-08 2000-02-10 Wolfgang Bergter Radioimmune drug for the treatment of HIV-1 infection
JP2002512261A (en) * 1998-04-15 2002-04-23 ベルクター，ヴォルフガンク CD4 radioimmune drug for treating HIV infection
WO1999055385A2 (en) * 1998-04-28 1999-11-04 Wolfgang Bergter Radioimmunopharmaca for treating hepatitis c
CA3147955A1 (en) 2017-02-15 2018-08-23 Systemex Energies Inc. Power control device
CN109251893A (en) * 2018-09-18 2019-01-22 深圳市宝迪生物工程有限公司 A kind of preparation method of in vitro placental hematopoietic stem cell

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009181A2 (en) * 1987-05-29 1988-12-01 Tanox Biosystems, Inc. Monoclonal antibodies neutralizing hiv-1
WO1989006967A1 (en) * 1988-02-03 1989-08-10 Xoma Corporation Immunosupression with anti-pan t-cell immunotoxin compositions
CA1339775C (en) * 1988-06-10 1998-03-24 Shuzo Matsushita Antibody 0.5b to hiv-i gp 120 modified with toxic substance
IL91070A (en) * 1988-07-23 1995-03-30 Us Commerce Cytotoxic agent against specific virus infection
CA2051107A1 (en) * 1989-04-25 1990-10-26 William N. Sun Antibodies specific for cd4-binding domain of hiv
DE69029036T2 (en) * 1989-06-29 1997-05-22 Medarex Inc SPECIFIC REAGENTS FOR AIDS THERAPY
DK0441917T3 (en) * 1989-07-25 1996-09-16 Oncogen Antiviral turmeric protein - monoclonal antibody conjugates

Also Published As

Publication number Publication date
WO1994004191A1 (en) 1994-03-03

Similar Documents

Publication Publication Date Title
GB2268074B (en) Medical devices
GB9203039D0 (en) Treatment
GB9222260D0 (en) Skin treatment
GB9217124D0 (en) Medical treatment
GB2303303B (en) Medical treatment
GB9521725D0 (en) Medical treatment
ZA953237B (en) Medical treatment
GB9526264D0 (en) Medical treatment
GB9222195D0 (en) Medical treatment
GB9204062D0 (en) Medical treatment
GB9218773D0 (en) Skin treatment
GB9321793D0 (en) Medical treatment
GB9122334D0 (en) Medical treatment
ZA925931B (en) Medicinal treatment
IL102796A0 (en) Medicinal treatment
GB9226313D0 (en) Therapeutic treatment
GB9026067D0 (en) Medical treatment
GB9024140D0 (en) Medical treatment
GB9206226D0 (en) Blood treatment system
GB9215903D0 (en) Treatment
GB9200359D0 (en) Treatment
GB9200360D0 (en) Treatment
GB9200361D0 (en) Treatment
GB9203249D0 (en) Treatment
GB9206395D0 (en) Treatment